Medicus Pharma (Medicus Pharma) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Asset Impairment Charge?

Medicus Pharma's Asset Impairment Charge for the three months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Medicus Pharma Asset Impairment Charge Historical Data

The historical data trend for Medicus Pharma's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Asset Impairment Charge Chart

Medicus Pharma Annual Data

Trend

Dec21

Dec22

Dec23

Asset Impairment Charge

Medicus Pharma Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial				-	-	-	-	-

Medicus Pharma Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Medicus Pharma Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Medicus Pharma's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Medicus Pharma (Medicus Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (OTCPK:MDPLF) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

MDCX:Canada

Address

100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4

Website

http://www.medicuspharma.com

Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

Medicus Pharma (Medicus Pharma) Headlines

From GuruFocus

Medicus Pharma Opens the Market

By PRNewswire • 10-26-2023